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ifosfamide in 2 pts (12%) and other regimens in 3 pts (18%). Pts
treated with ibrutinib received 560 mg p.o. daily. Intratechal CT was
added in 5 pts (31%) and 7 pts (47%) in standard and ibrutinib cohort.
Radiotherapy was delivered to 3 pts, all in the standard cohort, in one
case as consolidation and in 2 cases as salvage. With a median follow-
up of 10.4 months, the 1-year PFS and OS of the entire study popula-
tion are 24% and 46%. A statistically significant difference in 1-year
PFS was observed in favor of ibrutinib versus standard CT (49% vs
6%, p = 0.044). The difference in 1-year OS in favor of ibrutinib versus
standard CT did not reach statistical significance (57% vs 37%,
p = 0.097). In the standard cohort only one pt is alive after allogeneic
transplantation.
Conclusion: In this study, ibrutinib monotherapy appears to be effec-
tive for CNS-MCL; with the usual limitations of a retrospective analy-
sis, our data show a benefit in PFS for CNS-MCL pts treated with
ibrutinib in comparison to standard chemoimmunotherapy.
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Introduction: Zanubrutinib, an investigational BTK inhibitor, has dem-
onstrated greater selectivity for BTK vs other TEC- and EGFR-family
kinases in biochemical assays and shown favorable PK/PD properties
in preclinical studies. In phase 1 testing, high plasma concentrations
were achieved, resulting in complete and sustained 24-hour BTK inhi-
bition in blood and lymph nodes in patients (pts) treated at 160 mg
twice daily (bid; Tam. Blood 2016;128:642). Here, we present updated
safety and efficacy data from pts with MCL.
Methods: This is a global, phase 1 study investigating zanubrutinib in
pts with B-cell malignancies with indication-specific expansion
cohorts. In the expansion phase, enrolled pts received zanubrutinib
320 mg daily or 160 mg bid (the RP2D). Treatment emergent adverse
events (TEAEs) were summarized according to NCI CTCAE v4.03 and
responses were assessed by CT scans as per Lugano Classification
(Cheson. J Clin Oncol 2014;32:3059).
Results: As of 16 Sep 2018, 48 MCL pts were enrolled:
37 relapsed/refractory (R/R) and 11 treatment-naïve (TN) (Table). Of the
48 pts, 45 were evaluable for efficacy; 3 were not efficacy evaluable as
they had not yet reached the first 12-week efficacy assessment. Median
follow-up for efficacy evaluable pts was 16.0 mo (range, 1.6–38.2).
Twenty-six pts discontinued treatment (16 due to progressive disease
[PD]; 10 due to TEAEs including peripheral edema, small cell lung cancer,
renal hematoma, ANCA-positive vasculitis with acute kidney injury, sub-
dural hematoma, and myelodysplastic syndrome, pneumonia (2 pts), con-
gestive cardiac failure, thalamic infarction). Five pts died due to TEAEs
(1 pneumonia, 1 congestive cardiac failure, 1 thalamic infarction, and
2 sepsis/septic shock), none of which were assessed by investigator as
related to zanubrutinib. Most common TEAEs of any cause (≥15% of
pts) included diarrhea (35%), petechiae/purpura/contusion (31%), upper
respiratory tract infection (27%), fatigue (25%), constipation (21%), rash
(19%), back pain (17%), headache (17%) and peripheral edema (17%).
Overall response rate (ORR) for TN, R/R and overall was 87.5% (7/8),
86.5% (32/37) and 86.7% (39/45) respectively (Table). Responses were
based on computed tomography scans for most pts, as positron-
emission tomography was not required. Median progression-free sur-
vival was 15.4 mo (Table).
Conclusions: Zanubrutinib monotherapy was shown to be well toler-
ated and highly active in pts with MCL, with high ORR and rate of CR.
Keywords: BTK inhibitors; mantle cell lymphoma (MCL).
Disclosures: Tam, C: Honoraria: Beigene, Janssen, AbbVie, Novartis;
Research Funding: Janssen and AbbVie. Wang, M: Consultant Advisory
Role: BioInvent; IO Biotech; Celgene; Juno Therapeutics; Janssen;
Pharmacyclics; AstraZeneca; MoreHealth; Pulse BioSciences; AxImmune;
Stock Ownership:MoreHealth; Honoraria: Janssen; Dava Oncology; OMI;
PeerView Institute for Medical Education (PVI); Research Funding:
Janssen; AstraZeneca; Acerta Pharma; Kite Pharma; Juno Therapeutics;
BeiGene; Novartis; Celgene; BioInvent; Karus; Oncternal; Amgen; Other
Remuneration: Travel, Accommodations, Expenses: Janssen; AstraZeneca;
Dava Oncology; OMI. Simpson, D: Honoraria: Celgene, Janssen, Abbvie,
Roche; Research Funding: Amgen, Pharmacyclics, Acerta, Beigene,
Celgene, BMS, Roche, Sanofi, GSK; Other Remuneration: Travel, Accom-
modations, Expenses: Janssen, Celgene. Opat, S: Consultant Advisory
Role: Roche, Janssen, Abbvie, Celgene, Takeda, Merck, Gilead,
Mundipharma; Honoraria: Roche, Janssen, Abbvie, Celgene, Takeda,
Merck, Gilead, Mundipharma; Research Funding: BeiGene, Roche, Janssen,
ABSTRACT 245
Abbvie, Takeda, Merck, Gilead, Epizyme. Cull, G: Research Funding:
Beigene, Glycomimetics, Abbvie; Other Remuneration: Travel, Accommo-
dations, Expenses: Amgen, Roche. Munoz, J: Consultant Advisory Role:
Pharmacyclics LLC, Bayer, Gilead/Kite Pharma, Bristol-Myers Squibb,
Janssen, Juno/Celgene; Other Remuneration: Speaker's Bureau: Kite
Pharma, Gilead, Bayer, Pharmacyclics/Janssen, AstraZeneca. Phillips, T:
Consultant Advisory Role: Bayer, Gilead, Seattle Genetics, Genentech,
Incyte, Pharmacyclics; Research Funding: Pharmacyclics, Abbvie. Kim, W:
Research Funding: Roche, Takeda, Mundipharma, J&J, Celltrion, Kyowa
kirin, Donga. Atwal, S: Employment Leadership Position: BeiGene; Stock
Ownership: BeiGene; Research Funding: BeiGene; Other Remuneration:
Leadership: BeiGene. Wei, R: Employment Leadership Position: BeiGene;
TABLE 1 Patient Characteristics, Safety, and Efficacy
Patient characteristics N = 48
Median (range) age, y 71 (42–90)
ECOG PS, n (%)
0 20 (41.7)
1 22 (45.8)
2 6 (12.5)
Stage at study entry, n (%)
Stage I 3 (6.3)
Stage II 1 (2.1)
Stage III 4 (8.3)
Stage IV 40 (83.3)
MIPI, n (%)
Low risk 12 (25.0)
Intermediate risk 18 (37.5)
High risk 18 (37.5)
Disease status, n (%)
Treatment-naïve 11 (22.9)
Relapsed/refractory 37 (77.1)
Median (range) no. of prior therapies 1 (1–4)
Median (range) follow-up, mo 15.1 (0.6–38.2)
Bulky disease >10 cm, n (%) 3 (6.3)
Safety, n (%) N = 48
Any AE 47 (97.9)
Grade ≥3 AEs 28 (58.3)
Serious AEs 19 (39.6)
AEs leading to zanubrutinib discontinuation 11 (22.9)
AEs leading to death 5 (10.4)
Efficacy
Best response per investigator (n) TN (n=8) R/R (n=37) Overall (n=45)
Overall response rate, n (%); 95% CI 7 (87.5);
47.3, 99.7
32 (86.5);
71.2, 95.5
39 (86.7);
73.2, 94.9
Complete response, n (%) 3 (37.5) 11 (29.7) 14 (31.1)
Partial response, n (%) 4 (50.0) 21 (56.8) 25 (55.6)
Stable disease, n (%) 0 (0.0) 2 (5.4) 2 (4.4)
Progressive disease, n (%) 1 (12.5) 3 (8.1) 4 (8.9)
Median follow up (min, max) 8.6 (1.6, 25.0) 17.1 (1.9, 38.2) 16.0 (1.6, 38.2)
Duration of response (mo) R/R (n=32) Overall (n=39)
Follow up, median (min, max)a 14.7 (0.0, 28.2) 14.3 (0.0, 28.2)
Median (95% CI)b 14.7 (10.6, 18.5) 14.7 (10.6, 18.5)
Abbreviations: AE, adverse event; ECOG PS, Eastern Cooperative Oncology Group performance status; CI, confidence interval.
aFollow-up time is estimated by the reverse Kaplan-Meier method.
bMedian is estimated by Kaplan-Meier method with 95% CIs estimated using the Brookmeyer and Crowley method.
246 ABSTRACT
Stock Ownership: BeiGene. Huang, J: Employment Leadership Position:
BeiGene; Stock Ownership: BeiGene. Elstrom, R: Employment Leader-
ship Position: BeiGene; Stock Ownership: BeiGene. Trotman, J: Research
Funding: PCYC, Roche, Janssen, Celgene, BeiGene.
AGGRESSIVE LYMPHOMAS
192
THE CLINICAL COURSE OF DIFFUSE LARGE
B-CELL LYMPHOMA (DLBCL) OVER TIME: A
MULTISTATE SURVIVAL ANALYSIS USING
META-DATA FROM 13 FIRST-LINE
RANDOMIZED TRIALS
Ç. Çaglayan1 | J.G. Dixon2 | G. Salles3 | A. Wall2 |
N. Schmitz4 | D. Cunningham5 | V. Poeschel6 |
J. Seymour7 | U. Jaeger8 | T. Habermann9 |
F. Merli10 | C. Haioun11 | H. Tilly12 |
H. Ghesiquieres13 | M. Ziepert14 | J. Flament15 |
Q. Shi2 | C. Flowers16
1Industrial and Systems Engineering, Georgia Institute of Technology,
Atlanta, GA, United States; 2Department of Health Sciences Research,
Mayo Clinic, Rochester, MN, United States; 3Hematology, Hospices Civils
de Lyon, Lyon, France; 4Hematology and Oncology, University Hospital
Muenster, Muenster, Germany; 5Department of Medicine, The Royal
Marsden Hospital, Sutton, United Kingdom; 6Medical School, Saarland
University, Homburg, Germany; 7Clinical Research, Integrated
Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia;
8Department of Medicine I, Medical University of Vienna, Vienna,
Austria; 9Cancer Center, Hematology, Mayo Clinic, Rochester, MN,
United States; 10Hematology, AUSL-IRCCS, Reggio Emilia, Italy; 11Unite
Hemopathies Lymphoides, Hopital Henri Mondor, Creteil, France;
12Hématologie, Centre Henri-Becquerel, Rouen, France; 13Service
d'Hématologie, Centre Hospitalier Lyon-Sud, Pierre Bénite CEDEX,
France; 14Institut für Medizinische Informatik, Statistik und
Epidemiologie, Universität Leipzig, Leipzig, Germany; 15Medicine and
Biology, Celgene Corporation, Boudry, Switzerland; 16Winship Cancer
Institute, Emory University, Atlanta, GA, United States
Introduction: The Surrogate Endpoints for Aggressive Lymphoma
(SEAL) collaboration established a meta-database integrating individ-
ual patient data from 13 first-line randomized clinical trials on previ-
ously untreated diffuse large B-cell lymphoma (DLBCL). This meta-
database provides an opportunity to investigate the impact of clinical
factors and treatment response on DLBCL-specific and other causes
of death following initial therapy to define new opportunities for trials
and improve survivorship.
Methods: Using the SEAL database, we studied DLBCL outcomes for
patients receiving anthracycline-based chemotherapy with/without
added rituximab (R-Chemo) in a multistate survival analysis model
having the model states “Alive with No Progression of Disease (PoD)
after Treatment (TX)”, “Alive after PoD”, “Death from DLBCL”, and
“Death from Other Causes” (top Figure). The Aalen-Johansen estima-
tor was used to calculate the likelihood of being in each model state
and project the course of DLBCL over time (bottom Figure).
Results:We identified 7,911 DLBCL patients (Figure) with median age
62 (range 18-92) years, 62.1% stage III/IV, 64.7% IPI ≥ 2, including
5,108 treated with R-Chemo. Following initial TX for all patients
(or with R- Chemo), 2- and 5-year DLBCL-specific death rate were
7.5% (5.9%) and 8.8% (7.0%) for patients age < 40 at initial TX, 8.9%
(7.2%) and 12.8% (10.6%) for age 40-60, 10.4% (9.8%) and 15.2%
(14.6%) for age 60-70, and 12.8% (12.5%) and 18.3% (17.6%) for age
≥ 70. Death rates at 2- and 5-year from all other causes were 2.3%
(2.1%) and 3.5% (3.8%) for age < 40, 4% (3.1%) and 6.5% (5.1%) for
age 40-60, 5.1% (4.8%) and 9.4% (7.9%) for age 60-70, and 11.3%
(12.3%) and 18.3% (20.0%) for age ≥ 70. Following R- Chemo
(n = 5,108), 2-year PoD rates were 12.3% for patients achieving CR,
24.1% for PR, and 28.4% for SD; 2- and 5- year DLBCL-specific mor-
tality rates were 4.6% and 8.7% for CR, 11.8% and 18.6% for PR,
20.3% and 25.6% for SD, and 69.1% and 71.2% for PD. These rates
were similar for “non R-Chemo” regimens. International Prognostic
Index (IPI) affected the 2- and 5-year DLBCL-specific mortality rates,
which were 4.8% and 8% for IPI = 0 or 1, 7.8% and 11.9% for IPI =
2, 13.3% and 18.6% for IPI = 3, and 24.4% and 29.7% for IPI = 4 or
5 in the whole SEAL population (n = 7,911).
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